Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety (Q34558942)

3 August 2017

title

Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety (English)

1 reference

3 August 2017

1 reference

Geddes AM

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

Expert Opinion on Investigational Drugs

3 August 2017

published in

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

487-505

1 reference

Prospective study of the aetiology and outcome of pneumonia in the community

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Antimicrobial Resistance in Streptococcus pneumoniae: An Overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

21 January 2018

The pneumococcal problem

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Antagonism of GABAA receptors by 4-quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Selective antagonism of the GABA(A) receptor by ciprofloxacin and biphenylacetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Dissociated resistance among fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Postantibiotic effects of E-4868 and OPC-17116.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.487

21 January 2018

Identifiers

DOI

10.1517/13543784.8.4.487

1 reference

3 August 2017

1 reference